135 related articles for article (PubMed ID: 16152596)
1. Identification of a glioma antigen, GARC-1, using cytotoxic T lymphocytes induced by HSV cancer vaccine.
Iizuka Y; Kojima H; Kobata T; Kawase T; Kawakami Y; Toda M
Int J Cancer; 2006 Feb; 118(4):942-9. PubMed ID: 16152596
[TBL] [Abstract][Full Text] [Related]
2. Effective Treatment of Established GL261 Murine Gliomas through Picornavirus Vaccination-Enhanced Tumor Antigen-Specific CD8+ T Cell Responses.
Renner DN; Jin F; Litterman AJ; Balgeman AJ; Hanson LM; Gamez JD; Chae M; Carlson BL; Sarkaria JN; Parney IF; Ohlfest JR; Pirko I; Pavelko KD; Johnson AJ
PLoS One; 2015; 10(5):e0125565. PubMed ID: 25933216
[TBL] [Abstract][Full Text] [Related]
3. Elimination of regulatory T cells is essential for an effective vaccination with tumor lysate-pulsed dendritic cells in a murine glioma model.
Grauer OM; Sutmuller RP; van Maren W; Jacobs JF; Bennink E; Toonen LW; Nierkens S; Adema GJ
Int J Cancer; 2008 Apr; 122(8):1794-802. PubMed ID: 18076066
[TBL] [Abstract][Full Text] [Related]
4. Identification of HLA-A2- and A24-restricted T-cell epitopes derived from SOX6 expressed in glioma stem cells for immunotherapy.
Ueda R; Ohkusu-Tsukada K; Fusaki N; Soeda A; Kawase T; Kawakami Y; Toda M
Int J Cancer; 2010 Feb; 126(4):919-29. PubMed ID: 19728337
[TBL] [Abstract][Full Text] [Related]
5. Glioma antigen.
Toda M
Adv Exp Med Biol; 2012; 746():77-84. PubMed ID: 22639160
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapeutic targeting of shared melanoma-associated antigens in a murine glioma model.
Prins RM; Odesa SK; Liau LM
Cancer Res; 2003 Dec; 63(23):8487-91. PubMed ID: 14679014
[TBL] [Abstract][Full Text] [Related]
7. Immuno-viral therapy of brain tumors by combination of viral therapy with cancer vaccination using a replication-conditional HSV.
Toda M; Iizuka Y; Kawase T; Uyemura K; Kawakami Y
Cancer Gene Ther; 2002 Apr; 9(4):356-64. PubMed ID: 11960286
[TBL] [Abstract][Full Text] [Related]
8. Systemic inhibition of transforming growth factor-beta in glioma-bearing mice improves the therapeutic efficacy of glioma-associated antigen peptide vaccines.
Ueda R; Fujita M; Zhu X; Sasaki K; Kastenhuber ER; Kohanbash G; McDonald HA; Harper J; Lonning S; Okada H
Clin Cancer Res; 2009 Nov; 15(21):6551-9. PubMed ID: 19861464
[TBL] [Abstract][Full Text] [Related]
9. Sequential delivery of interferon-alpha gene and DCs to intracranial gliomas promotes an effective antitumor response.
Tsugawa T; Kuwashima N; Sato H; Fellows-Mayle WK; Dusak JE; Okada K; Papworth GD; Watkins SC; Gambotto A; Yoshida J; Pollack IF; Okada H
Gene Ther; 2004 Nov; 11(21):1551-8. PubMed ID: 15343358
[TBL] [Abstract][Full Text] [Related]
10. Recognition of herpes simplex virus antigens on the surface of mouse cells of the H-2b haplotype by virus-specific cytotoxic T lymphocytes.
Jennings SR; Rice PL; Pan S; Knowles BB; Tevethia SS
J Immunol; 1984 Jan; 132(1):475-81. PubMed ID: 6197457
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic effect of a T helper cell supported CTL response induced by a survivin peptide vaccine against murine cerebral glioma.
Ciesielski MJ; Kozbor D; Castanaro CA; Barone TA; Fenstermaker RA
Cancer Immunol Immunother; 2008 Dec; 57(12):1827-35. PubMed ID: 18438666
[TBL] [Abstract][Full Text] [Related]
12. Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models.
Zhu X; Nishimura F; Sasaki K; Fujita M; Dusak JE; Eguchi J; Fellows-Mayle W; Storkus WJ; Walker PR; Salazar AM; Okada H
J Transl Med; 2007 Feb; 5():10. PubMed ID: 17295916
[TBL] [Abstract][Full Text] [Related]
13. Glioma-specific cytotoxic T cells can be effectively induced by subcutaneous vaccination of irradiated wild-type tumor cells without artificial cytokine production.
Iwadate Y; Yamaura A; Sakiyama S; Sato Y; Tagawa M
Int J Oncol; 2003 Aug; 23(2):483-8. PubMed ID: 12851699
[TBL] [Abstract][Full Text] [Related]
14. Cross-reactive recognition of mouse cells expressing the bm3 and bm11 mutations within H-2Kb by H-2Kb-restricted herpes simplex virus-specific cytotoxic T lymphocytes.
Jennings SR
J Immunol; 1985 Nov; 135(5):3530-6. PubMed ID: 2413124
[TBL] [Abstract][Full Text] [Related]
15. Exosomes from Dendritic Cells Loaded with Chaperone-Rich Cell Lysates Elicit a Potent T Cell Immune Response Against Intracranial Glioma in Mice.
Bu N; Wu H; Zhang G; Zhan S; Zhang R; Sun H; Du Y; Yao L; Wang H
J Mol Neurosci; 2015 Jul; 56(3):631-43. PubMed ID: 25680514
[TBL] [Abstract][Full Text] [Related]
16. Identification of interleukin-13 receptor alpha2 peptide analogues capable of inducing improved antiglioma CTL responses.
Eguchi J; Hatano M; Nishimura F; Zhu X; Dusak JE; Sato H; Pollack IF; Storkus WJ; Okada H
Cancer Res; 2006 Jun; 66(11):5883-91. PubMed ID: 16740728
[TBL] [Abstract][Full Text] [Related]
17. A dendritic cell vaccine induces protective immunity to intracranial growth of glioma.
Insug O; Ku G; Ertl HC; Blaszczyk-Thurin M
Anticancer Res; 2002; 22(2A):613-21. PubMed ID: 12014629
[TBL] [Abstract][Full Text] [Related]
18. Cytotoxic T lymphocytes specific for herpes simplex virus (HSV) studied using adenovirus vectors expressing HSV glycoproteins.
Witmer LA; Rosenthal KL; Graham FL; Friedman HM; Yee A; Johnson DC
J Gen Virol; 1990 Feb; 71 ( Pt 2)():387-96. PubMed ID: 2155292
[TBL] [Abstract][Full Text] [Related]
19. Induction of protective and therapeutic antitumor immunity by a DNA vaccine with a glioma antigen, SOX6.
Ueda R; Kinoshita E; Ito R; Kawase T; Kawakami Y; Toda M
Int J Cancer; 2008 May; 122(10):2274-9. PubMed ID: 18224680
[TBL] [Abstract][Full Text] [Related]
20. Genetic vaccination against the melanocyte lineage-specific antigen gp100 induces cytotoxic T lymphocyte-mediated tumor protection.
Schreurs MW; de Boer AJ; Figdor CG; Adema GJ
Cancer Res; 1998 Jun; 58(12):2509-14. PubMed ID: 9635569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]